221 related articles for article (PubMed ID: 38703250)
1. Research progress of immunotherapy for advanced head and neck cancer.
Sun A; Xing Z; Lv R; Niu P; Zhao B; Ma S; Li H
Med Oncol; 2024 May; 41(6):133. PubMed ID: 38703250
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
3. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
Guidi A; Codecà C; Ferrari D
Med Oncol; 2018 Feb; 35(3):37. PubMed ID: 29441454
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
6. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
7. Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients.
Chen G; Wu Q; Jiang H; Li Z; Hua X; Hu X; Yu H; Xie C; Zhong Y
J Hematol Oncol; 2020 Dec; 13(1):174. PubMed ID: 33308264
[TBL] [Abstract][Full Text] [Related]
8. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.
Hughes RT; Gebeyehu RR; Kalada JM; Lycan TW; Frizzell BA; Kinney RD; D'Agostino RB; Bunch PM; Triozzi P; Zhang W; Furdui CM; Porosnicu M
Future Oncol; 2023 Jul; 19(22):1523-1534. PubMed ID: 37199326
[TBL] [Abstract][Full Text] [Related]
9. [Immune checkpoint inhibitor therapy in advanced head and neck cancer].
Hang W; Xu ZX; Zhang Q; Lu X; Liu G
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 52(1):67-70. PubMed ID: 28104022
[TBL] [Abstract][Full Text] [Related]
10. Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice.
Wang HC; Yeh TJ; Chan LP; Hsu CM; Cho SF
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076306
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():791621. PubMed ID: 35003112
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint immunotherapy in head and neck cancers.
Zolkind P; Uppaluri R
Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
[TBL] [Abstract][Full Text] [Related]
13. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
14. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
15. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
Lorini L; Gili R; Salvestrini V; Morelli I; Smussi D; Petrelli F; Bonomo P; Bossi P
Oral Oncol; 2024 May; 152():106768. PubMed ID: 38552469
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy: Who Is Eligible?
Wang D; Gilbert J; Kim YJ
Otolaryngol Clin North Am; 2017 Aug; 50(4):867-874. PubMed ID: 28755708
[TBL] [Abstract][Full Text] [Related]
17. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
18. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
Park R; Park JC
Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
[TBL] [Abstract][Full Text] [Related]
19. An update on the immune landscape in lung and head and neck cancers.
Carlisle JW; Steuer CE; Owonikoko TK; Saba NF
CA Cancer J Clin; 2020 Nov; 70(6):505-517. PubMed ID: 32841388
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]